Evolving strategies for renoprotection: non-diabetic chronic renal disease.
Experimental and clinical studies over the past two decades have identified several interventions for slowing the progression of chronic renal disease towards end-stage renal failure. In this paper we review the experimental and clinical evidence in support of dietary protein restriction, angiotensin-converting enzyme inhibitor therapy, control of systemic hypertension, reduction of proteinuria, treatment of hyperlipidemia and smoking cessation. We also consider potential future renoprotective therapies. Finally we propose a comprehensive strategy for achieving maximal renoprotection with available interventions and monitoring.
Taal
M W
MW
Renal Unit, Nottingham City Hospital, Hucknall Road, Nottingham, UK.
Brenner
B M
BM
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018753:Diet, Protein-Restricted; D006801:Humans; D006949:Hyperlipidemias / Q000628:therapy; D006973:Hypertension / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D015260:Neprilysin / Q000037:antagonists & inhibitors; D011507:Proteinuria / Q000628:therapy; D016540:Smoking Cessation
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D015260:Neprilysin